{"id":59887,"date":"2026-03-18T16:35:21","date_gmt":"2026-03-18T08:35:21","guid":{"rendered":"https:\/\/flcube.com\/?p=59887"},"modified":"2026-03-18T16:35:21","modified_gmt":"2026-03-18T08:35:21","slug":"alebund-pharma-licenses-ap306-to-r1-therapeutics-usd-100-million-deal-for-first-in-class-hyperphosphatemia-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59887","title":{"rendered":"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug"},"content":{"rendered":"\n<p><strong>Alebund Pharmaceuticals<\/strong> has entered into an <strong>exclusive licensing agreement<\/strong> with <strong>R1 Therapeutics, Inc. (UK)<\/strong> for <strong>AP306<\/strong>, a <strong>first\u2011in\u2011class pan\u2011phosphate transporter inhibitor<\/strong>, granting R1 <strong>development, manufacturing, and commercialization rights outside Greater China<\/strong> in a transaction valued at up to <strong>USD 100 million<\/strong> in milestones plus tiered royalties and equity participation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Deal Type<\/strong><\/td><td>Exclusive out\u2011licensing (ex\u2011Greater China)<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>Alebund Pharmaceuticals (Shanghai\u2011based)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>R1 Therapeutics, Inc. (UK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>AP306 \u2013 first\u2011in\u2011class pan\u2011phosphate transporter inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Up to <strong>USD 100 million<\/strong> (development, regulatory, commercial milestones)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered, <strong>low double\u2011digit percentage<\/strong> on net sales<\/td><\/tr><tr><td><strong>Equity Component<\/strong><\/td><td>Alebund obtains R1 equity with <strong>anti\u2011dilution protection<\/strong><\/td><\/tr><tr><td><strong>Development Funding<\/strong><\/td><td>R1 funds and <strong>co\u2011leads global clinical development<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>AP306<\/strong> \u2013 <strong>first\u2011in\u2011class pan\u2011phosphate transporter inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Origin:<\/strong> Discovered by <strong>Chugai Pharmaceutical (Japan)<\/strong>; licensed to Alebund Pharma<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li><strong>Novel approach vs. traditional phosphate binders<\/strong> (sevelamer, lanthanum, calcium acetate)<\/li>\n\n\n\n<li><strong>Inhibits active phosphorus transport<\/strong> through three key GI phosphate transporters:\n<ul class=\"wp-block-list\">\n<li><strong>NaPi\u2011IIb<\/strong> (sodium\u2011phosphate cotransporter IIb)<\/li>\n\n\n\n<li><strong>PiT\u20111<\/strong> (phosphate transporter 1)<\/li>\n\n\n\n<li><strong>PiT\u20112<\/strong> (phosphate transporter 2)<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Targets phosphorus absorption at molecular level vs. binding\u2011based chelation; potential for improved efficacy, reduced pill burden, and better gastrointestinal tolerability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-status-amp-global-strategy\">Development Status &amp; Global Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Status<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase IIa completed in hemodialysis patients<\/td><td>De\u2011risked with human efficacy\/safety data<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>Global <strong>Phase IIb MRCT<\/strong> (multi\u2011regional clinical trial)<\/td><td>US + China initiation planned <strong>H2 2026<\/strong><\/td><\/tr><tr><td><strong>Development Leadership<\/strong><\/td><td>R1 funds and <strong>co\u2011leads<\/strong> global development with Alebund<\/td><td>Shared investment reduces Alebund capital burden; accelerates timeline<\/td><\/tr><tr><td><strong>Geographic Split<\/strong><\/td><td>Alebund retains <strong>Greater China rights<\/strong>; R1 controls ex\u2011China<\/td><td>Optimized regional expertise: Alebund (China regulatory\/commercial); R1 (US\/EU development)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hyperphosphatemia Market Dynamics:<\/strong> Global CKD\u2011dialysis population exceeds <strong>3 million patients<\/strong>; hyperphosphatemia affects >80% of hemodialysis patients with current binder therapies generating <strong>US$1.5\u20112 billion<\/strong> annually \u2013 but compliance limited by pill burden (8\u201112 tablets\/day) and GI side effects.<\/li>\n\n\n\n<li><strong>AP306 Differentiation:<\/strong> Pan\u2011transporter inhibition offers <strong>mechanistic novelty<\/strong> with potential for once\u2011daily oral dosing vs. multi\u2011tablet binder regimens; Phase IIa data demonstrated phosphorus reduction efficacy with favorable safety profile \u2013 supports premium pricing vs. generic binders if Phase IIb\/III successful.<\/li>\n\n\n\n<li><strong>Alebund Strategic Validation:<\/strong> USD 100 million milestone potential validates Chugai origin asset and Alebund&#8217;s clinical development execution; equity stake in R1 with anti\u2011dilution protection provides upside participation in R1 future financing\/IPO without additional cash investment.<\/li>\n\n\n\n<li><strong>R1 Therapeutics Positioning:<\/strong> UK\u2011based biotech gains first\u2011in\u2011class asset with completed Phase IIa, established mechanism, and clear regulatory pathway; co\u2011funding structure aligns Alebund incentives with R1 development success; MRCT design positions for simultaneous US FDA and China NMPA registration.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> AP306 competes against established binders (Sanofi&#8217;s sevelamer, Fresenius&#8217;s calcium acetate) and emerging non\u2011binder approaches (tenapanor \u2013 Ardelyx); first\u2011in\u2011class transporter inhibition provides differentiation narrative for formulary access and nephrologist adoption.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievement probabilities, clinical development timelines, and commercial expectations for AP306. Actual results may differ due to risks including Phase IIb trial design challenges, competitive dynamics in hyperphosphatemia, and regulatory requirements in multiple jurisdictions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[627,4646],"class_list":["post-59887","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-alebund-pharmaceuticals","tag-r1-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for AP306, a first\u2011in\u2011class pan\u2011phosphate transporter inhibitor, granting R1 development, manufacturing, and commercialization rights outside Greater China in a transaction valued at up to USD 100 million in milestones plus tiered royalties and equity participation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59887\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug\" \/>\n<meta property=\"og:description\" content=\"Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for AP306, a first\u2011in\u2011class pan\u2011phosphate transporter inhibitor, granting R1 development, manufacturing, and commercialization rights outside Greater China in a transaction valued at up to USD 100 million in milestones plus tiered royalties and equity participation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59887\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T08:35:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59887#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59887\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug\",\"datePublished\":\"2026-03-18T08:35:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59887\"},\"wordCount\":551,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alebund Pharmaceuticals\",\"R1 Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59887#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59887\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59887\",\"name\":\"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-18T08:35:21+00:00\",\"description\":\"Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for AP306, a first\u2011in\u2011class pan\u2011phosphate transporter inhibitor, granting R1 development, manufacturing, and commercialization rights outside Greater China in a transaction valued at up to USD 100 million in milestones plus tiered royalties and equity participation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59887#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59887\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59887#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug - Insight, China&#039;s Pharmaceutical Industry","description":"Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for AP306, a first\u2011in\u2011class pan\u2011phosphate transporter inhibitor, granting R1 development, manufacturing, and commercialization rights outside Greater China in a transaction valued at up to USD 100 million in milestones plus tiered royalties and equity participation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59887","og_locale":"en_US","og_type":"article","og_title":"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug","og_description":"Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for AP306, a first\u2011in\u2011class pan\u2011phosphate transporter inhibitor, granting R1 development, manufacturing, and commercialization rights outside Greater China in a transaction valued at up to USD 100 million in milestones plus tiered royalties and equity participation.","og_url":"https:\/\/flcube.com\/?p=59887","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T08:35:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59887#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59887"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug","datePublished":"2026-03-18T08:35:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59887"},"wordCount":551,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alebund Pharmaceuticals","R1 Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59887#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59887","url":"https:\/\/flcube.com\/?p=59887","name":"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-18T08:35:21+00:00","description":"Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for AP306, a first\u2011in\u2011class pan\u2011phosphate transporter inhibitor, granting R1 development, manufacturing, and commercialization rights outside Greater China in a transaction valued at up to USD 100 million in milestones plus tiered royalties and equity participation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59887#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59887"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59887#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alebund Pharma Licenses AP306 to R1 Therapeutics \u2013 USD 100 Million Deal for First\u2011in\u2011Class Hyperphosphatemia Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59887"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59887\/revisions"}],"predecessor-version":[{"id":59889,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59887\/revisions\/59889"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}